HomeREGULATORY
REGULATORY

CSIMC Recommends NHI Price Listing for 15 APIs/20 Products
(Sep.7.2011)

At a general meeting on September 7, the Central Social Insurance Medical Council (CSIMC; Chuikyo) recommended NHI price listing for 15 APIs (active pharmaceutical ingredients)/20 products, including AstraZeneca’s proton pump inhibitor (PPI) Nexium capsule 10 mg and 20 mg (esomeprazole magnesium) and Astellas Pharma’s treatment for overactive bladder Betanis Tablet 25 mg and 50 mg (mirabegron). The adrenal hormone preparation EpiPen Injection 0.15 mg and 0.3 mg (adrenaline) will be added to the NHI price list on September 22. Other products will be included in the NHI price list on September 12.
> Read full story

Commentary

How Will Industry Counter Proposed Re-Pricing of “Huge Seller” Drugs?

Lexicon

Pricing premium for the promotion of new drug development and the elimination/resolution of off-label use:
新薬創出・適応外薬解消等促進加算(新薬創出加算)

The Column

What’s Your Pharma Company’s Brand in Japan?

Archives

FPMAJ Wants Continuation of Innovation Premium, No Market Price-Based Price Revision in 2017: Chuikyo Hearings(Aug.27)
Chuikyo’s HTA Panel Issues Interim Report, Appraisal Results to Be Used to Re-Price Selected Listed Drugs(Aug.27)
Development Projects, Regulatory Filings Increasing Thanks to Innovation Premium: PhRMA, EFPIA(Aug.27)
Ono Files for Multiple Myeloma Treatment Carfilzomib in Japan(Aug.27)
Lixiana Recommended by UK’s NICE as Venous Thromboembolism Treatment Under National Health Service: Daiichi Sankyo(Aug.27)

News Calendar